Jounce Gets $47M Series A, Seeks to Jolt Cancer Therapy
Third Rock Ventures LLC plumbed its considerable network and assembled a team of prestigious cancer biologists and immunotherapy experts to form Jounce Therapeutics Inc., which launched Thursday with a $47 million Series A financing.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST